Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists more than 30 years ago, our science-driven approach has resulted in seven FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

 

 

NEWSROOM

  • Jan 28

    FDA Accepts for Priority Review Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
  • Jan 22

    Forty of the Nation's Brightest Young Scientists Named Finalists in Regeneron Science Talent Search 2020

EVENTS

Events
  • Regeneron Pharmaceuticals Q4 2019 Earnings Conference Call
    Feb 6
    8:00 AM EST
    Feb 6, 2020 | 8:00 AM EST